GO:0032561 guanyl ribonucleotide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032561 (guanyl ribonucleotide binding) is a molecular function describing the binding of any guanosine esterified with phosphate or oligophosphate at any ribose hydroxyl group, including GTP, GDP, GMP, and cGMP.
• This binding activity is central to signal transduction by heterotrimeric G proteins, small GTPases, and guanylyl cyclase receptors [4,5].
• Guanyl nucleotide binding modulates diverse targets, including steroid receptors in neuronal membranes and bacterial toxin substrates [3,5].
• Dysregulation of guanyl ribonucleotide binding underlies retinal diseases, cardiovascular disorders, and neurological conditions [1,7,8].
• Key experimental models include knockout and point-mutation cell lines for G proteins, guanylyl cyclases, and GTPase regulators [1,2,6].
• CRISPR-based knockout, knock-in, and overexpression platforms enable precise interrogation of guanyl ribonucleotide binding proteins in disease contexts [6,8].
Description
Guanyl ribonucleotide binding (GO:0032561) is a fundamental molecular function that governs how cells recognize and respond to guanine-based nucleotides such as GTP, GDP, GMP, and cyclic GMP. This binding activity is not merely a passive interaction; it is the switch that controls a vast array of cellular processes, from sensory perception and neurotransmission to cell growth and immune responses [4,5]. The term encompasses any protein domain capable of non-covalently interacting with a guanyl ribonucleotide, and it is essential for the function of heterotrimeric G proteins, small GTPases, and guanylyl cyclase receptors [4,5]. Researchers study guanyl ribonucleotide binding to understand how extracellular signals are converted into intracellular changes. For example, in retinal photoreceptor outer segments, guanylate cyclase activating proteins (GCAPs) regulate membranous guanylate cyclase (ROS-GC) in a manner dependent on guanyl nucleotides and ATP, linking this binding activity directly to vision and retinal disease. Similarly, bacterial toxins such as cholera toxin and pertussis toxin ADP-ribosylate guanyl nucleotide-binding regulatory proteins, disrupting their function and causing severe pathologies. The importance of this term extends to pharmacology and drug discovery. Soluble guanylate cyclase (sGC) is a heme-containing enzyme that binds GTP and is stimulated by nitric oxide; its dysfunction is implicated in cardiovascular diseases, and pharmacological stimulators and activators of sGC are used therapeutically [7,8]. Thus, GO:0032561 provides a unifying framework for understanding a wide range of physiological and pathological processes.
guanyl ribonucleotide binding At A Glance
| GO ID | GO:0032561 |
|---|---|
| GO term | guanyl ribonucleotide binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to guanyl ribonucleotides such as GTP, GDP, GMP, and cGMP |
| Definition source | QuickGO |
| Related molecular functions | GTP binding, GDP binding, cyclic GMP binding, guanylyl nucleotide exchange factor activity |
| Representative protein families | Heterotrimeric G proteins, small GTPases, guanylyl cyclases, GTPase-activating proteins |
| Disease relevance | Retinal degeneration, cardiovascular disease, neurological disorders, bacterial toxin pathogenesis |
What Is GO:0032561?
According to the Gene Ontology, GO:0032561 (guanyl ribonucleotide binding) is defined as the binding to a guanyl ribonucleotide, any compound consisting of guanosine esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety. In simpler terms, it is the ability of a protein to physically attach to a guanine-containing nucleotide such as GTP, GDP, GMP, or cGMP. This binding can be transient or stable and often induces conformational changes that regulate protein activity.
Why Is guanyl ribonucleotide binding Important in Cell Biology?
Guanyl ribonucleotide binding is a cornerstone of cellular signaling because it allows proteins to act as molecular switches that cycle between active and inactive states. This function is essential for the fidelity of signal transduction pathways that control vision, neurotransmission, cardiac contractility, and cell proliferation [4,5]. Disruptions in this binding activity are directly linked to human diseases, including retinal dystrophies, hypertension, and neurological disorders [1,7,8]. Moreover, because many pathogens exploit guanyl nucleotide-binding proteins, this term is also critical for understanding infectious disease mechanisms.
• Enables heterotrimeric G proteins to relay signals from cell surface receptors to intracellular effectors.
• Controls the activity of small GTPases that regulate cell growth, cytoskeleton, and vesicle trafficking.
• Mediates nitric oxide sensing by soluble guanylate cyclase, a key regulator of vascular tone [7,8].
• Is required for photoreceptor function and adaptation in the retina, with defects causing retinal diseases.
• Modulates steroid receptor binding in neuronal membranes, influencing neuroendocrine responses.
• Serves as a target for bacterial toxins that ADP-ribosylate G proteins, leading to diseases like cholera.
• Provides a mechanism for cGMP signaling in organisms such as Dictyostelium, affecting chemotaxis and development.
• Underpins optogenetic tools based on enzymerhodopsins that bind guanyl nucleotides.
• Is a focus for pharmacological intervention using sGC stimulators and activators in cardiovascular therapy.
• Offers a rich source of targets for CRISPR-based disease modeling and drug discovery [1,6,8].
Molecular Mechanism of guanyl ribonucleotide binding
Nucleotide Binding Pocket and Specificity
In simple terms: Proteins that bind guanyl ribonucleotides have a pocket that fits GTP or GDP like a lock and key.
The binding of guanyl ribonucleotides occurs through a conserved nucleotide-binding pocket that recognizes the guanine base, ribose sugar, and phosphate groups. Specificity for guanine over adenine is achieved by hydrogen bonding with the O6 and N1 positions of the purine ring. Proteins such as heterotrimeric G protein alpha subunits and small GTPases (e.g., Ras, Rho) use this pocket to bind GTP or GDP with high affinity. Guanylyl cyclase receptors also bind GTP as a substrate, and their catalytic domains share structural features with adenylyl cyclases. The binding energy is used to induce conformational changes that propagate to effector domains.
GTP Hydrolysis and Conformational Switching
In simple terms: When GTP is cut into GDP, the protein changes shape and turns off its signal.
Many guanyl ribonucleotide-binding proteins function as molecular switches by hydrolyzing GTP to GDP. The active state is typically GTP-bound, while the inactive state is GDP-bound. GTP hydrolysis is catalyzed by intrinsic GTPase activity, often accelerated by GTPase-activating proteins (GAPs). Guanine nucleotide exchange factors (GEFs) promote the release of GDP and rebinding of GTP, completing the cycle. This cycle is essential for the temporal control of signaling. For example, in retinal photoreceptors, GCAPs regulate ROS-GC in a GTP-dependent manner, and ATP modulates this process, linking nucleotide binding to visual adaptation.
Regulation by Accessory Proteins and Effectors
In simple terms: Other proteins can help or hinder the binding of guanyl nucleotides, tuning the signal.
Accessory proteins regulate guanyl ribonucleotide binding by altering nucleotide affinity or hydrolysis rates. GAPs and GEFs are key regulators, as are guanine nucleotide dissociation inhibitors (GDIs). In nitric oxide-sensitive guanylyl cyclase, binding of GTP is influenced by the heme group and by allosteric modulators. Pharmacological stimulators and activators of soluble guanylate cyclase can enhance or mimic GTP binding, leading to increased cGMP production. Additionally, bacterial toxins such as cholera toxin ADP-ribosylate G protein alpha subunits, locking them in a GTP-bound state and causing constitutive activation.
Cyclic GMP Binding and Downstream Signaling
In simple terms: Some proteins bind cGMP, a circular form of GMP, to control many cellular responses.
Cyclic GMP (cGMP) is a guanyl ribonucleotide that binds to specific effector proteins, including cGMP-dependent protein kinases (PKGs), cyclic nucleotide-gated channels, and phosphodiesterases. The binding of cGMP to these targets regulates smooth muscle relaxation, platelet aggregation, and neuronal signaling. In Dictyostelium, cGMP signaling is analyzed to understand chemotaxis and development, and methods for studying cGMP binding are well established. The diversity of cGMP-binding proteins highlights the broad impact of GO:0032561.
Structural Basis and Allostery
In simple terms: The shape of the protein changes when it grabs a guanyl nucleotide, like a hand squeezing a ball.
Structural studies have revealed that guanyl ribonucleotide binding often induces allosteric changes that are transmitted over long distances. For instance, in enzymerhodopsins, which are light-activated guanylyl cyclases, the binding of GTP and its conversion to cGMP are coupled to conformational changes in the rhodopsin domain. Similarly, the binding of guanyl nucleotides to steroid receptors in neuronal membranes modulates receptor affinity and function, demonstrating that this binding activity extends beyond classical G proteins. These allosteric mechanisms are critical for the specificity and timing of cellular responses.
Key Genes Involved in GO:0032561 guanyl ribonucleotide binding
The following genes encode proteins that directly bind guanyl ribonucleotides or regulate this binding activity, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GNAS | Encodes Gs alpha subunit; binds GTP and activates adenylyl cyclase | Mutations cause McCune-Albright syndrome and endocrine tumors |
| GNAI1 | Encodes Gi alpha subunit; binds GTP and inhibits adenylyl cyclase | Involved in neuronal signaling and cancer |
| HRAS | Small GTPase that binds GTP to regulate cell growth | Oncogenic mutations are common in cancers |
| KRAS | Small GTPase that binds GTP to control proliferation | Major driver in pancreatic and lung cancers |
| NRAS | Small GTPase that binds GTP to regulate survival | Mutated in melanoma and leukemia |
| RHO | Small GTPase that binds GTP to regulate cytoskeleton | Linked to retinal degeneration and cancer |
| RAC1 | Small GTPase that binds GTP to control motility | Implicated in cancer invasion and immune disorders |
| GUCY1A1 | Subunit of soluble guanylate cyclase; binds GTP as substrate | Target for cardiovascular drugs [7,8] |
| GUCY1B1 | Subunit of soluble guanylate cyclase; binds GTP and heme | Mutations cause hypertension and platelet dysfunction [7,8] |
| GUCY2D | Retinal guanylate cyclase; binds GTP to produce cGMP | Mutations cause Leber congenital amaurosis |
| GUCA1A | GCAP1; regulates retinal guanylate cyclase in a GTP-dependent manner | Mutations cause cone-rod dystrophy |
| GUCA1B | GCAP2; regulates retinal guanylate cyclase | Associated with retinal degeneration |
| GNB1 | Beta subunit of heterotrimeric G proteins; binds guanyl nucleotides indirectly | Mutations cause neurological disorders |
| GNGT1 | Gamma subunit of transducin; binds GTP-bound alpha subunit | Essential for visual signal transduction |
| ARF1 | Small GTPase that binds GTP to regulate vesicle trafficking | Involved in Golgi function and cancer |
| RAB7A | Small GTPase that binds GTP to control endosomal transport | Mutations cause Charcot-Marie-Tooth disease |
| RAN | Small GTPase that binds GTP to regulate nucleocytoplasmic transport | Overexpressed in many cancers |
How Is guanyl ribonucleotide binding Regulated?
Guanyl ribonucleotide binding is regulated at multiple levels. The nucleotide-bound state is controlled by the opposing actions of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), which respectively promote GTP loading and hydrolysis. Guanine nucleotide dissociation inhibitors (GDIs) can sequester proteins in an inactive, GDP-bound form. Post-translational modifications, such as ADP-ribosylation by bacterial toxins, can lock G proteins in a GTP-bound state, leading to constitutive signaling. In retinal photoreceptors, ATP and GCAPs modulate the guanylate cyclase activity that depends on GTP binding, providing an additional layer of regulation. Pharmacological agents, including soluble guanylate cyclase stimulators and activators, directly influence GTP binding and cGMP production.
guanyl ribonucleotide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GUCY2D | Leber congenital amaurosis, cone-rod dystrophy | Knockout and knock-in mouse models; patient iPSC-derived retinal organoids |
| GUCA1A | Cone-rod dystrophy | Point-mutation knock-in mice; overexpression in cell lines |
| GUCY1A1 | Hypertension, cardiovascular disease | Knockout rats; sGC stimulator testing in vitro [7,8] |
| KRAS | Pancreatic, lung, and colorectal cancer | Knockout and point-mutation (G12D) cell lines; xenograft models |
| GNAS | McCune-Albright syndrome, pituitary tumors | Knock-in mice with activating mutations; CRISPR-edited cell lines |
Retinal Degeneration and Guanyl Ribonucleotide Binding
Mutations in genes encoding retinal guanylate cyclase (GUCY2D) and its activating proteins (GUCA1A, GUCA1B) impair GTP binding and cGMP production, leading to photoreceptor death and diseases such as Leber congenital amaurosis and cone-rod dystrophy. The binding of guanyl nucleotides to ROS-GC is essential for visual adaptation, and its disruption causes severe vision loss.
Cardiovascular Disease and Soluble Guanylate Cyclase
Soluble guanylate cyclase (sGC) binds GTP and is activated by nitric oxide to produce cGMP, which relaxes blood vessels. Dysfunction of sGC, often due to oxidative stress or mutations, contributes to hypertension, heart failure, and pulmonary hypertension. Pharmacological stimulators and activators of sGC enhance GTP binding or mimic its effects, offering therapeutic benefits.
Cancer and Small GTPases
Oncogenic mutations in small GTPases such as KRAS, HRAS, and NRAS lock the proteins in a GTP-bound active state, driving uncontrolled proliferation. These mutations are among the most common in human cancers, making guanyl ribonucleotide binding a prime target for drug development.
Neurological Disorders and G Protein Signaling
Guanyl nucleotide binding modulates steroid receptor function in neuronal membranes, influencing neuroendocrine responses. Additionally, mutations in G protein subunits (e.g., GNB1) cause neurological disorders with developmental delay and seizures. Bacterial toxins that ADP-ribosylate G proteins can also lead to neurological symptoms.
From guanyl ribonucleotide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GUCY2D affect photoreceptor survival? | Knockout mouse or retinal organoids |
| How does a specific point mutation in KRAS alter GTP binding? | Point-mutation knock-in cell lines (e.g., G12V) |
| Can a tagged G protein be used to track nucleotide binding in live cells? | Knock-in of fluorescent tag (e.g., GFP) at endogenous locus |
| What is the effect of overexpressing GCAP1 on retinal guanylate cyclase activity? | Overexpression in HEK293 or photoreceptor cell lines |
| Which genes regulate cGMP signaling in Dictyostelium? | Knockout and overexpression in Dictyostelium discoideum |
| Can sGC activators rescue hypertension in a knockout model? | Knockout rat treated with pharmacological stimulators [7,8] |
How to Study the guanyl ribonucleotide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTPγS binding assay | G protein activation by guanyl nucleotides | Screening for G protein-coupled receptor agonists |
| cGMP radioimmunoassay | Production of cGMP from GTP | Measuring guanylate cyclase activity in retinal extracts |
| X-ray crystallography | Atomic structure of nucleotide-binding pocket | Designing inhibitors of small GTPases |
| FRET-based biosensors | Real-time GTP binding dynamics | Live-cell imaging of signaling in Dictyostelium |
| CRISPR knockout screen | Genes required for guanyl nucleotide-dependent growth | Identifying cancer vulnerabilities |
| ADP-ribosylation assay | Toxin-mediated modification of G proteins | Studying bacterial pathogenesis |
| Optogenetic control | Light-dependent cGMP production | Controlling neuronal activity with enzymerhodopsins |
| Pharmacological profiling | Effects of sGC stimulators/activators | Testing cardiovascular drugs |
GTP Binding Assays
Radioactive or fluorescent GTP binding assays are used to measure the affinity and kinetics of guanyl ribonucleotide binding. These assays often employ [35S]GTPγS, a non-hydrolyzable analog, to assess G protein activation. For guanylyl cyclase, GTP conversion to cGMP can be monitored by radioimmunoassay or mass spectrometry [1,7].
Structural Biology
X-ray crystallography and cryo-electron microscopy provide atomic-level views of guanyl ribonucleotide binding pockets and conformational changes. Structures of G proteins, small GTPases, and guanylyl cyclases have revealed the molecular basis of nucleotide specificity and allostery [4,6].
Live-Cell Imaging of Nucleotide Dynamics
Genetically encoded fluorescent biosensors, such as GTP sensors, allow real-time monitoring of guanyl ribonucleotide binding in living cells. These tools have been applied to study G protein activation and cGMP dynamics in various organisms [2,6].
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that regulate guanyl ribonucleotide binding and downstream signaling. Such screens have been used to uncover modifiers of drug response in cancer cells and to map signaling networks [4,8].
How CRISPR Can Be Used to Study GO:0032561 guanyl ribonucleotide binding
Knockout
CRISPR knockout of genes encoding guanyl ribonucleotide-binding proteins, such as GUCY2D or KRAS, allows researchers to assess loss-of-function phenotypes. For example, GUCY2D knockout in retinal organoids recapitulates features of Leber congenital amaurosis, while KRAS knockout inhibits cancer cell proliferation [1,4].
Point Mutation
Point mutations can be introduced to mimic disease-associated variants, such as the G12D mutation in KRAS or mutations in GUCA1A linked to cone-rod dystrophy. These models help dissect how specific amino acid changes alter nucleotide binding affinity and downstream signaling [1,4].
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes at endogenous loci enables tracking of protein localization and nucleotide binding in real time. Knock-in of disease mutations into model organisms provides more physiologically relevant disease models [1,4].
Overexpression
Overexpression of wild-type or mutant guanyl ribonucleotide-binding proteins, such as GCAP1 or sGC subunits, can be achieved via lentiviral transduction or CRISPR activation. This approach is useful for studying gain-of-function effects and for drug screening [1,7,8].
How EDITGENE Supports guanyl ribonucleotide binding Research
Researchers studying guanyl ribonucleotide binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for guanyl ribonucleotide binding research.
Frequently Asked Questions About guanyl ribonucleotide binding
What is guanyl ribonucleotide binding?
Guanyl ribonucleotide binding (GO:0032561) is the molecular function of binding to a guanine-containing nucleotide such as GTP, GDP, GMP, or cGMP. It is essential for many signaling proteins.
What genes are involved in guanyl ribonucleotide binding?
Key genes include GNAS, GNAI1, HRAS, KRAS, NRAS, RHO, RAC1, GUCY1A1, GUCY1B1, GUCY2D, GUCA1A, and GUCA1B, among others [1,4,7].
How does guanyl ribonucleotide binding relate to disease?
Mutations in these genes can cause retinal degeneration, cardiovascular disease, cancer, and neurological disorders [1,4,7,8].
What is the difference between GTP and GDP binding?
GTP binding usually activates signaling proteins, while GDP binding keeps them inactive. The cycle between these states is regulated by GEFs and GAPs.
Which proteins bind cyclic GMP?
cGMP binds to protein kinase G, cyclic nucleotide-gated channels, and phosphodiesterases, regulating smooth muscle relaxation and neuronal signaling.
How can I study guanyl ribonucleotide binding in the lab?
Common methods include GTPγS binding assays, cGMP radioimmunoassays, structural biology, and live-cell imaging with biosensors [1,2,4].
What are CRISPR models for guanyl ribonucleotide binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes like KRAS, GUCY2D, and GNAS to study their function [1,4].
Why is soluble guanylate cyclase important?
Soluble guanylate cyclase binds GTP and produces cGMP in response to nitric oxide, regulating blood pressure. Its dysfunction is targeted by cardiovascular drugs [7,8].
What is the role of guanyl nucleotides in retinal diseases?
In photoreceptors, GTP binding to ROS-GC and its regulation by GCAPs are critical for vision. Defects cause Leber congenital amaurosis and cone-rod dystrophy.
How does EDITGENE support research on guanyl ribonucleotide binding?
EDITGENE provides custom CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics services for genes in this pathway.
Conclusion
Guanyl ribonucleotide binding (GO:0032561) is a pervasive molecular function that underpins diverse signaling pathways, from vision and cardiovascular control to cell growth and neuroendocrine regulation. Its dysregulation is implicated in major human diseases, making it a rich area for both basic and translational research [1,4,7,8]. Advances in CRISPR-based genome editing now allow precise modeling of nucleotide-binding proteins, accelerating the discovery of new therapeutic targets. EDITGENE's comprehensive services empower researchers to dissect these mechanisms with confidence.
References
- 1. Bondarenko VA et al.. 2010. Involvement of rhodopsin and ATP in the activation of membranous guanylate cyclase in retinal photoreceptor outer segments (ROS-GC) by GC-activating proteins (GCAPs): a new model for ROS-GC activation and its link to retinal diseases.. Mol Cell Biochem 334(1-2):125-39 PMID: 19941040
- 2. van Haastert PJM et al.. 2024. Analysis of cGMP Signaling in Dictyostelium.. Methods Mol Biol 2814:177-194 PMID: 38954206
- 3. Orchinik M et al.. 1992. Guanyl nucleotides modulate binding to steroid receptors in neuronal membranes.. Proc Natl Acad Sci U S A 89(9):3830-4 PMID: 1570300
- 4. Garbers DL et al.. 1994. Guanylyl cyclase receptors.. Mol Biol Cell 5(1):1-5 PMID: 7910495
- 5. Moss J et al.. 1988. ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins.. Adv Enzymol Relat Areas Mol Biol 61:303-79 PMID: 3128060
- 6. Tsunoda SP et al.. 2021. Molecular Properties and Optogenetic Applications of Enzymerhodopsins.. Adv Exp Med Biol 1293:153-165 PMID: 33398812
- 7. Friebe A et al.. 2003. Regulation of nitric oxide-sensitive guanylyl cyclase.. Circ Res 93(2):96-105 PMID: 12881475
- 8. Petraina A et al.. 2025. Revisiting soluble guanylate cyclase pharmacology: Additive potential of stimulators and activators.. Biomed Pharmacother 193:118762 PMID: 41252787
